{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.57","value":"-12.2"},{"groupId":"OG001","spread":"35.30","value":"-8.2"},{"groupId":"OG002","spread":"30.88","value":"-10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"55"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.72","value":"-21.2"},{"groupId":"OG001","spread":"46.99","value":"-16.2"},{"groupId":"OG002","spread":"40.79","value":"18.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.12","value":"-18.2"},{"groupId":"OG001","spread":"143.83","value":"9.6"},{"groupId":"OG002","spread":"110.20","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"26"}],"units":"Participants"}],"title":"Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"84"}],"units":"Participants"}],"description":"Change from baseline is shown as: Percent change from baseline (BL) =((Post BL value - BL value)/ BL value)\\*100. Ferriman-Gallway scoring was used: 0=minimum and 36 was maximum in females only.","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined: 600 μg bid group includes all patients whose mean daily dose \\< 1500 μg /day.","id":"OG000","title":"Pasireotide 600 μg"},{"description":"Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined : 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day","id":"OG001","title":"Pasireotide 900 μg"},{"description":"Patients received pasireotide 600 μg or 900 μg BID","id":"OG002","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Number of patients with available data differed at visits","reportingStatus":"POSTED","timeFrame":"Baseline, week 12, 24 and 48","title":"Percent Change in Cushing's Disease Clinical Signs and Symptoms - Hirsutism","type":"SECONDARY","unitOfMeasure":"percent change in scores"}